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Mass Reduction and Functional Improvement of the Left Ventricle 
after Aortic Valve Replacement for Degenerative Aortic Stenosis
Sumin  Shin,  M.D.*,  Pyo  Won  Park,  M.D.,  Ph.D.*,  Woo-Sik  Han,  M.D.*,  Ki  Ick  Sung,  M.D.,  Ph.D.*, 
Wook  Sung  Kim,  M.D.,  Ph.D.*,  Young  Tak  Lee,  M.D.,  Ph.D.*
Background:  Left ventricular (LV) hypertrophy caused by aortic valve stenosis (AS) leads to cardiovascular morbid-
ity and mortality. We sought to determine whether aortic valve replacement (AVR) decreases LV mass and im-
proves LV function. Materials and Methods: Retrospective review for 358 consecutive patients, who underwent 
aortic valve replacement for degenerative AS between January 1995 and December 2008, was performed. There 
were 230 men and 128 women, and their age at operation was 63.2±10 years (30∼85 years). Results: There 
was no in-hospital mortality, and mean follow-up duration after discharge was 48.9 months (2∼167 months). 
Immediate postoperative echocardiography revealed that LV mass index and mean gradient across the aortic valve 
decreased significantly (p＜0.001), and LV mass continued to decrease during the follow-up period (p＜0.001). LV 
ejection fraction (EF) temporarily decreased postoperatively (p＜0.001), but LV function recovered immediately and 
continued to improve with a significant difference between preoperative and postoperative EF (p＜0.001). There 
were 15 late deaths during the follow-up period, and overall survival at 5 and 10 years were 94% and 90%, 
respectively. On multivariable analysis, age at operation (p=0.008), concomitant coronary bypass surgery (p＜0.003), 
lower preoperative LVEF (＜40%) (p=0.0018), and higher EUROScore (＞7) (p=0.045) were risk factors for late 
death.  Conclusion: After AVR for degenerative AS, reduction of left ventricular mass and improvement of left ven-
tricular function continue late after operation.
Key words: 1. Aortic valve replacement
2. Aortic stenosis
3. Left ventricular hypertrophy
INTRODUCTION
Degenerative  aortic  valve  stenosis  (AS)  is  one  of  the  most 
frequently  encountered  acquired  heart  disease  [1].  The  prog-
nosis  of  symptomatic  AS  with  severe  left  ventricular  hyper-
trophy  is  very  poor,  and  expected  survival  after  the  develop-
ment  of  symptoms,  such  as  dyspnea,  syncope  and  angina,  is 
less  than 2  years [2].  Severe AS  in elderly is also  associated 
w i t h  a  h i g h  m o r t a l i t y ,  a n d  l i f e  expectancy  of  octogenarians 
with  severe  AS  is  known  to  be  less  than  1  year  [1].  Aortic 
valve  replacement  (AVR)  employing  cardiopulmonary  bypass 
has  been  the  standard  treatment  for  patients  with  severe  AS. 
Left  ventricular  (LV)  hypertrophy,  which  is  caused  by  pres-
sure  overload  of  the  LV,  is  believed  to  increase  the  risk  of 
heart  failure,  cerebrovascular  accident  and  sudden  death.  Left 
ventricular  mass  index  (LVMI)  is  an  indicator  of  LV  hyper-Sumin Shin, et al
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Table 1. Patient profiles
Clinical    variables Value
Age  (years)   
  M e a n ±SD  (range)
Sex
    Male,  No.  (%)
    Female,  No.  (%)
Nationality
    Korean,  No.  (%)
    Foreigner,  No.  (%)
N Y H A  F c ,  N o .  ( % )
  I
  I I
  I I I
  I V
Preoperative  state,  No.  (%)
    Inotropic  agent
    Mechanical  ventilator  apply
    ECMO  support
Co-morbidities,  No.  (%)
    Coronary  artery  disease
  H y p e r t e n s i o n
    Diabetics  mellitus
  C V A
  C O P D
Smoking  History
    Current  smoker
  E x - s m o k e r
Euroscore   
  M e a n ±SD  (range)
63.2±10  (30∼85)
230  (64)
128  (36)
  355  (99.2)
   3  ( 0 . 8 )
  48  (13)
208  (58)
  91  (25)
11  (3)
 1 6   ( 4 . 5 )
   2  ( 0 . 6 )
   1  ( 0 . 3 )
    48  (13.4)
133  (37)
  55  (15)
 1 2   ( 3 . 4 )
14  (4)
  96  (27)
  56  (16)
4.9±2.5  (2∼15)
SD=Standard  deviation;  NYHA  Fc=New  York  heart  associa-
tion  functional  class;  ECMO=Extra-corporeal  membrane  oxygen-
ation;  CVA=Cerebrovascular  accident  (stroke);  COPD=Chronic 
obstructive  pulmonary  disease.
Fig. 1. Aortic valve replacement for various etiologies. AR=Aortic 
regurgitation; AVR=Aortic valve replacement; AS=Aortic stenosis; 
CAD=Coronary artery disease; CABG=Coronary artery bypass graft.
trophy, and LVMI is known to decrease after the reduction of 
LV  afterload  by  AVR  [3].  However,  decrease  in  LVMI  after 
AVR  is  slow  or  stagnant  in  some  patients,  and  late  outcome 
of AVR in this subset is reportedly worse than that of others 
with rapid regression of LV hypertrophy [4], which may well 
be attributed to left ventricular diastolic dysfunction and sten-
otic  nature  of  ventricular  hypertrophy  with  mal-coordination 
between the LV and prosthetic aortic valve [5]. In this study, 
we sought to determine the impact of AVR on LV mass and 
function,  and  we  conducted  risk  factor  analysis  for  late  mor-
tality  after  AVR. 
MATERIALS AND METHODS
Among the 407 patients who underwent AVR for AS from 
January  1995  to  December  2008,  358  patients  were  selected 
for  the  analysis  after  excluding  12  with  rheumatic  valvular 
heart  disease  and  37  patients  who  underwent  coronary  artery 
bypass  surgery  with  concomitant  AVR  for  moderate  AS 
which  did  not  correspond  to  our  indications  for  AVR  (Fig. 
1).  There  were  230  men  and  128  women,  and  their  age  at 
operation  was  63.2±10  years  (30∼85  years).  Among  them, 
102  patients  (102/358,  28.5%)  were  older  than  70  years,  and 
12 (12/358, 3.5%) were older than 80 years. Preoperative var-
iables,  such  as  New  York  heart  association  (NYHA)  func-
tional class, smoking history, European system for cardiac op-
erative  risk  evaluation  (Euroscore)  [6],  and  the  presence  of 
co-morbidities,  such  as  cerebrovascular  disease,  coronary  ar-
tery  disease,  hypertension,  chronic  obstructive  lung  disease, 
carotid  artery  obstruction,  were  reviewed  to  summarize  the 
clinical  characteristics  of  the  cohort  and  to  analyze  the  risk 
factors  for  late  death.  One-hundred  and  two  (102/358,  28%) 
were  in  NYHA  class  III,  16  were  on  preoperative  inotropic 
agents,  two  were  on  artificial  ventilator,  and  one  was  on  ex-
tra-corporeal  membrane  oxygenation  (Table  1).  Echocardio-
graphy  was  performed  preoperatively  and  immediate  post-
operatively  to  assess  the  postoperative  changes  of  left  ven-
tricular  ejection  fraction  (EF,  %),  mean  gradient  across  the 
a o r t i c  v a l v e  ( m m H g ) ,  a n d  l e f t  ventricular  mass  indexed  by 
body surface area (g/m
2). Follow-up echocardiographic exami-
nations  were  performed  between  6  and  12  months  post-Aortic Valve Replacement for Degenerative Aortic Stenosis
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operatively, and annually from then on. Coronary angiography 
was routinely performed for male patients older than 40 years 
and  female  patients  older  than  45  years.  Cardiac  computed 
tomography  and  carotid  doppler  examination  were  also  rou-
t i n e l y  p e r f o r m e d  f o r  p a t i e n t s  o l der  than  60  years  to  diagnose 
carotid  artery  disease  and  ascending  aortic  calcification  / 
dilatation. 
1) Indications for AVR
Before 2006, AVR was indicated for significant AS, which 
had  been  defined  as  presence  of  symptoms,  aortic  valve  area 
of less than 1 cm
2 or mean pressure gradient across the aortic 
valve  of  greater  than  50  mmHg  [7].  From  2006,  ACC/AHA 
guideline  [8]  has  been  applied  to  AVR  for  AS,  that  is,  pres-
ence of symptoms, mean systolic pressure gradient across the 
aortic valve of greater than 40 mmHg, peak systolic flow ve-
locity across the aortic valve of greater than 4 m/sec, and the 
association  of  coronary  artery  disease  which  necessitates  sur-
gical  intervention.  For  the  diagnosis  of  concealed  severe  AS 
in patients with LV dysfunction  and low  trans-aortic pressure 
gradient,  dobutamine  stress  echocardiography  was  conducted.
2) Surgical technique
Under  general  anesthesia  and  installation  of  trans-esoph-
ageal  echocardiography  probe,  surgical  procedures  were  per-
formed  through  median  sternotomy  and  moderately  hypo-
thermic  cardiopulmonary  bypass.  Supra-annular  prosthetic 
valve  implantation  technique  has  been  employed  from  2003. 
In  principle,  tissue  valves  were  used  for  the  elderly  (＞65 
years)  and  mechanical  valves  were  used  in  the  younger 
patients. 
3) Statistical analysis
Data  were  presented  as  mean  with  standard  deviation  or 
median  with  ranges.  To  compare  the  preoperative  and  imme-
diate  postoperative  echocardiographic  data,  paired  t-test  was 
used.  To  assess  the  trends  of  changes  in  echocardiographic 
data  during  the  follow-up  period,  repeated  measure  ANOVA 
(analysis  of  variance)  was  used.  Survival  was  plotted  using 
Kaplan-Meier method, and risk factors for late death were an-
alyzed  by  Cox  proportional  hazards  model.  Preoperative  and 
operative variables, such as age at operation, sex, presence of 
coronary  artery  disease,  NYHA  functional  class  of  III  or  IV, 
Euroscore  of  greater  than  7,  postoperative  pressure  gradient 
across the aortic valve of greater than 20 mmHg, preoperative 
LVEF  of  lower  than  40%,  and  concomitant  coronary  bypass 
surgery,  were  included  for  the  risk  factor  analysis  of  late 
death. A p-value of less than 0.05 was considered significant, 
and  SPSS  (Version  17.0,  SPSS  Inc.,  Chicago,  IL,  USA)  was 
used  for  statistical  analysis. 
RESULTS
There  was  no  in-hospital  mor t a l i t y ,  a n d  m e a n  f o l l o w - u p  
duration  after  discharge  was  48.9  months  (2∼167  months). 
Follow-up was complete in 97% of the  patients, and most of 
them  (83%)  have  been  followed  up  in  our  institution.  Survi-
v a l  o f  t h e  p a t i e n t s  w h o  w e r e  m i s s i n g  f r o m  f o l l o w - u p  ( 2 . 7 % )  
was  ascertained  using  the  database  from  the  ‘Statistics 
Korea’.  Immediate  postoperative  echocardiography  revealed 
that LV mass index decreased significantly (156±48.6 g/m
2 to 
140±5.2  g/m
2,  p＜0.001),  and  LV  mass  continued  to  regress 
during  the  follow-up  period  (p＜0.001)  (Table  2,  Fig.  2). 
Mean  pressure  gradient  across  the  aortic  valve  decreased  sig-
nificantly  on  immediate  postoperative  echocardiography 
(57.9±17.6  mmHg  to  13.5±5.2  mmHg,  p＜0.001),  and  re-
mained  lower  than  preoperative  value  during  the  follow-up 
period  (p＜0.001)  (Table  2,  Fig.  3).  The  use  of  Medtron-
ic-halls  valve  was  associated  with  significantly  greater  de-
crease in mean pressure gradient across the aortic valve com-
pared  to  the  use  of  ATS  (advancing  the  standard)  valve  (p
＜0.005) (Table 3). Preoperative LV ejection fraction (LVEF) 
was 55±11%, including 33 patients in 30∼40% range and 12 
patients  lower  than  30%.  Mean  LVEF  temporarily  decreased 
postoperatively  (58±13%  to  55±11%,  p＜0.001),  but  LV 
function  recovered  immediately  and  continued  to  improve 
with  a  significant  difference  between  preoperative  and  post-
operative EF (p＜0.001) (Table 2, Fig. 2). There were 15 late 
deaths during the follow-up period: six died of malignant ne-
oplasm, 3 died of congestive heart failure and 2 died of cere-
brovascular  accident  (Table  4).  Overall  survival  at  5  and  10 
years were 94% and 90%, respectively. Among the 3 patients 
who  died  of  congestive  heart  failure,  2  had  preoperative 
LVEF of lower than 40%. On univariable analysis, age at op-Sumin Shin, et al
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Table 2. Echocardiographic findings 
LV  mass  (g/m
2)
Pre
(n=319)
Post
(n=304)
p-value
0.5∼1.5  yr
(n=241)
1.5∼3  yr
(n=149)
3  yr＜
(n=69)
p-value*
Mean
SD
Median
Min
Max
156
 4 9
150
 5 9
386
140
 4 2
137
 6 0
312
＜0.001 112
 3 3
108
 4 7
305
103
 2 6
 9 9
 5 5
186
104
 2 6
100
 6 5
177
＜0.001
Mean  pressure  gradient  of  AoV  (%)
Pre
(n=348)
Post
(n=350)
p-value
0.5∼1.5  yr
(n=258)
1.5∼3  yr
(n=149)
3∼5  yr
(n=77)
5  yr∼
(n=57)
p-value*
Mean
SD
Median
Min
Max
≥20
57.93
17.58
55
17
122
13.49
 5 . 1 9
13
 4
48
31
＜0.001 12.92
 5 . 4 9
12
3
48
24
13.22
 6 . 0 2
12
3
47
9
14.85
 5 . 9 5
14
3
29
14
16.88
 7 . 4 0
15
7
44
14
＜0.001
LVEF  (%)
Pre
(n=323)
Post
(n=302)
p-value
0.5∼1.5  yr
(n=241)
1.5∼3  yr
(n=137)
3∼5  yr
(n=73)
5  yr∼
(n=56)
p-value*
Mean
SD
Median
Min
Max
58
13
61
15
86
54.90
10.85
56
24
82
＜0.001 62.53
 8 . 1 5
63
28
81
63.59
 7 . 3 8
65
431
80
62.91
 6 . 4 6
63
50
78
64.23
 5 . 6 2
64
55
75
＜0.001
LV=Left  ventricular;  SD=Standard  deviation;  AoV=Aortic  valve;  LVEF=Left  ventricular  ejection  fraction;  *Companison  of  early  and 
late  follow-up.
Fig. 2. Postoperative changes of left ventricular mass index and ejection fraction. LV=The left ventricle; LVEF=Left ventricular ejection 
fraction.Aortic Valve Replacement for Degenerative Aortic Stenosis
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Fig. 3. Postoperative changes of pressure gradient across the 
aortic valve. AoV=The aortic valve; PG=Pressure gradient. 
Table 4. Causes of late mortality
Variable No.  of  patients  (%)
Late  mortality
Causes  of  mortality
    Malignancy
    Congestive  heart  failure
  C V A
    Liver  cirrhosis
  B i l i a r y  s e p s i s
  S u d d e n  d e a t h
    Unknown 
15  (4)
6  (1.7)
3  (0.8)
2  (0.6)
1  (0.3)
1  (0.3)
1  (0.3)
1  (0.3)
CVA=Cerebrovascular  accident  (stroke).
Table 3. Mean trans-aortic PG according to the types of pros-
thetic aortic valve
Valve No.
Mean  PG  of  aortic  valve 
(mmHg)±SD
Preoperative
Immediate 
postoperative
Mechanical  (45%)
  A T S
  M e d - H a l l
  O n - X
    St.  Jude  Regent
  O t h e r s
Tissue  (55%)
    CE  Perimount
  C E  M a g n a
  O t h e r s
163
 3 7
 3 2
 3 5
 5 4
  5
195
 6 1
110
 2 1
61.6±23
59.3±17
64.2±17
53.7±15
61.6±18
55.8±16
16.2±9
11.1±4
11.9±4
12.3±5
14.7±4
13.8±5
PG=Pressure  gradient;  SD=Standard  deviation;  ATS=Advancing 
the  standard;  CE=Carpentier-Edwards.
Table 5. Risk factors for late death
Clinical    variable
Univariate 
analysis
Multivariate 
analysis
p-value p-value
Sex
Age 
Coronary  artery  disease
Previous  MI 
NYHA  Fc  lll-lV 
Euroscore 
Preoperative  LVEF  (%)
Postoperative  AoV  mean  PG  (≥20)
Concomitant  CABG
0.277
0.005
0.081
0.001
0.333
0.066
0.037
0.240
＜0.001
0.008
0.003
0.045
0.018
0.006
MI=Myocardial  infarction;  NYHA  Fc=New  York  heart  associa-
tion  functional  class;  LVEF=Left  ventricular  ejection  fraction; 
AoV=Aortic  valve;  PG=Pressure  gradient;  CABG=Coronary  ar-
t e r y  b y p a s s  g r a f t i n g  s u r g e r y .
eration  (p=0.005),  concomitant  coronary  bypass  surgery  (p
＜0.001)  and  preoperative  LVEF  of  lower  than  40% 
(p=0.0037)  were  risk  factors  for  late  death.  On  multivariable 
analysis,  age  at  operation  (p=0.008),  concomitant  coronary 
bypass  surgery  (p＜0.003),  preoperative  LVEF  of  lower  than 
40% (p=0.0018), and EUROScore (p=0.045) were risk factors 
for  late  death  (Table  5).
DISCUSSION
Ventricular hypertrophy is an adaptation process of the left 
ventricle  (LV)  to  cope  with  chronic  pressure  overload  caused 
by  aortic  stenosis.  In  the  earlier  phase,  ventricular  hyper-
trophy is beneficial for the generation of adequate stroke vol-
ume  and  cardiac  output  across  the  stenotic  aortic  valve,  but 
prolonged exposure to severe pressure overload leads to after-
load  mismatch  with  ventricular  systolic  dysfunction  and  de-
creased  pressure  gradient  across  the  aortic  valve.  In  this  set-
ting,  aortic  valve  replacement  (AVR)  is  known  to  alleviate 
heart  failure  symptoms  and  improve  left  ventricular  function 
[9,10].  Adequate  dimension  of  the  left  ventricular  outflow Sumin Shin, et al
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tract  (LVOT)  is  the  key  to  successful  outcome  because  in-
appropriate size of the prosthetic AV is the main cause of re-
sidual  pressure  gradient  across  the  AV  [11].  However,  ven-
tricular  hypertrophy,  which  is  attributed  to  chronic  pressure 
overload  to  the  LV,  is  believed  to  be  more  important  prog-
nostic  factor  than  the  pressure  gradient  across  the  prosthetic 
AV [12]. In a study pertaining to systemic hypertension, ven-
tricular  hypertrophy  was  associated  with  decreased  survival 
by  myocardial  ischemia,  systolic  and  diastolic  dysfunction, 
and  ventricular  arrhythmia  which  may  lead  to  sudden  death 
[ 1 3 , 1 4 ] .  T o  t h e  c o n t r a r y ,  A V R  f o r  a o r t i c  s t e n o s i s  i s  r e -
portedly associated with left ventricular mass reduction, stabi-
lization  of  the  ventricular  electrical  instability,  and  improve-
ments  in  myocardial  ischemia,  and,  hence,  improved  func-
tional capacity and long-term outcome [11]. In  this study,  re-
duction of the ventricular mass was observed immediate post-
operatively,  and  LV  mass  continued  to  regress  as  time 
passed.  Delay in  the improvements  in LV  ejection  fraction  is 
believed  to  be  associated  with  myocardial  fibrosis  [15].   
Mortality  after  AVR  in  octogenarians  has  reportedly  de-
creased  from  14%  [16]  to  2.4∼5%  [17,18],  which  is  con-
s i s t e n t  w i t h  t h e  r e s u l t s  f r o m  t h i s  s t u d y .  I n  o u r  s e r i e s ,  t h e r e  
was  no  early  mortality  regardless  of  the  age  at  operation  or 
the  presence  of  associated  cardiac  diseases,  and  one  of  the 
major  causes  of  late  deaths  was  malignancy.  Three  patients 
died  of  congestive  heart  failure,  two  of  whom  showed  de-
creased LV ejection fraction (＜40%) preoperatively. risk fac-
tors  for  late  death  turned  out  to  be  age  at  operation,  con-
comitant coronary artery bypass surgery, and preoperative LV 
dysfunction  (LV  ejection  fraction  ＜40%).  In  other  reports, 
postoperative  changes  in  NYHA  functional  class  [19]  and 
pressure gradient across the AV [20] were identified as prog-
nostic  factors  for  late  survival. 
One  of the  peri-operative  factors  which excellent  early  and 
late outcome of this series could be attributed to is our vigo-
rous  attempts  to  ascertain  any  calcification  in  the  thoracic 
aorta.  To  this  end,  we  routinely  conducted  preoperative  car-
diac  computed  tomography,  intra-operative  transesophageal 
echocardiographic  monitoring,  and,  more  recently,  intra-oper-
ative  epiaortic  echocardiography  prior  to  the  surgical  inter-
vention  of  the  aorta.  Relatively  younger  age  at  operation 
compared  to  other  series,  AVR  by  cardiac  surgeons  who  ex-
clusively  perform  valve  surgery,  and  higher  valve  size-body 
weight  ratio  with  lower  postoperative  residual  trans-aortic 
pressure  gradient could well be  contributing  factors  for  better 
outcome  too.  To  implant  bigger-sized  prosthetic  valves,  we 
have  employed  supra-annular  valve  implantation  technique 
and  aortic  annulus  enlargement  procedures.  Thanks  to  these 
aggressive  maneuvers,  only  24  patients  (6.7%)  showed  re-
sidual  mean  trans-aortic  gradient  greater  than  20  mmHg  on 
postoperative one-year echocardiography (Table 2). Retrospec-
tive study design, and, as a result, significant missing data in 
the  earlier  cohort,  are  limitations  of  this  study.   
CONCLUSION
After  aortic  valve  replacement,  left  ventricular  mass  index 
significantly  decreased  immediate  postoperatively  and  con-
tinued  to  decrease,  while  left  ventricular  function  deteriorated 
immediate  postoperatively  but  gradually  improved  during  the 
follow-up  period.  Lower  preoperative  left  ventricular  ejection 
fraction  was  identified  as  a  risk  factor  for  late  mortality.
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